SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
1.640
-0.200 (-10.87%)
At close: Dec 15, 2025, 4:00 PM EST
1.680
+0.040 (2.44%)
After-hours: Dec 15, 2025, 7:46 PM EST
SciSparc Employees
SciSparc had 2 employees as of December 31, 2024. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
$653,000
Profits / Employee
-$3,240,000
Market Cap
2.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 0 | - |
| Dec 31, 2021 | 3 | 1 | 50.00% |
| Dec 31, 2020 | 2 | -6 | -75.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRC News
- 13 days ago - SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - GlobeNewsWire
- 13 days ago - Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company - TheNewswire
- 14 days ago - SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio - GlobeNewsWire
- 19 days ago - SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems - GlobeNewsWire
- 25 days ago - SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - GlobeNewsWire
- 26 days ago - Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - TheNewswire
- 7 weeks ago - SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio - GlobeNewsWire
- 7 weeks ago - SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewsWire